Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline
Janet B. McGill,Rajiv Agarwal,Stefan D. Anker,George L. Bakris,Gerasimos Filippatos,Bertram Pitt,Luis M. Ruilope,Andreas L. Birkenfeld,M. Luiza Caramori,Meike Brinker,Amer Joseph,Andrea Lage,Robert Lawatscheck,Charlie Scott,Peter Rossing +14 more
TL;DR: In this article , the effect of finerenone by baseline HbA1c, HbAA1c variability, diabetes duration and baseline insulin use on cardiorenal outcomes and diabetes progression was evaluated.
5
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter]
Julio Rosenstock,Vivian Fonseca,Janet B. McGill,Matthew C. Riddle,J.-P. Hallé,Irene Hramiak,P. Johnston,M. Davis +7 more
TL;DR: The selection of the patient population and the exclusion of established proliferative DR in the study, comments on the protective effects of metformin against cancer, proposes multiple arbitrary post hoc subgroup analyses, and notes that insulin glargine and NPH insulin resulted in similar glycaemic control are questioned.
Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network
Janet B. McGill,Mengdi Wu,Rodica Pop-Busui,Kara Mizokami-Stout,William V. Tamborlane,Grazia Aleppo,Rose Gubitosi-Klug,Michael J. Haller,Steven M Willi,Nicole C. Foster,Chelsea Zimmerman,Ingrid Libman,Sarit Polsky,Michael R. Rickels +13 more
TL;DR: Improving modifiable risk factors, including glucose and blood pressure control, remain important to reduce the risk of DKD in T1D.
4
Anti-Diabetes Therapy: Safety Considerations for Patients With Impaired Kidney Function
TL;DR: Of the classes of antihyperglycemic drugs discussed in this review, caution is advised when using some classes in patients with T2DM and kidney disease, particularly the sulfonylureas.
3
•Journal Article
Severe ovarian hyperstimulation syndrome in patients with autoimmune disorders: a report of two cases.
TL;DR: T1DM, with or without other concomitant autoimmune diseases, may increase the risk for severe OHSS and awareness of the interaction of preexisting conditions and risk for vascular leak disorders is needed for comprehensive counseling prior to embarking on ovarian stimulation.
3